



**Ref. No.: EIKO/BSE/2023-24/38**

**Date: 09<sup>th</sup> November 2023**

To,  
Corporate Services Department,  
**BSE Limited**,  
P J Towers,  
1st Floor, Dalal Street,  
Fort, Mumbai - 400001.

Scrip Code: 540204

**Sub: Newspaper Publication**

Dear Sir, Pursuant to Reg. 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached scanned copy of the newspaper publication of unaudited Financial Results of the Company for the quarter and half year ended 30<sup>th</sup> September, 2023 duly approved in the Board Meeting held on 08<sup>th</sup> November, 2023 published in the Financial Express (in English) and Mumbai Lakshadweep (in Marathi).

Copy of the results are also uploaded on the website of our Company - [www.eikolifesciences.com](http://www.eikolifesciences.com).

Kindly disseminate the above information on your website for the information of shareholders.

Thanking you, Yours sincerely


**For Eiko Lifesciences Limited**

JAID  
ISMAIL  
KOJAR

Digitally signed  
by JAID ISMAIL  
KOJAR  
Date: 2023.11.09  
12:50:12 +05'30'

**Jaid Ismail Kojar**  
**Chief Financial Officer**

**Encl:** Same as above

 <b>EIKO LIFESCIENCES LIMITED</b> <small>FEEL THE CHEMISTRY</small> [Formerly known as Narendra Investments (Delhi) Ltd.] (CIN: L65993MH1977PLC258134) Regd off: 604, Centrum, Opp. TMC Office, Near Satkar Grand Hotel, Wagle Estate, Thane West MH 400604 <b>EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER &amp; HALF YEAR ENDED SEPTEMBER 30, 2023</b> (₹ in Lakhs Except EPS)							
Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Unaudited)	30.09.2023 (unaudited)	30.09.2022 (unaudited)	31-03-2023 (Audited)
1	Total Income from Operations	644.09	653.50	453.62	1,297.59	781.19	1,917.62
2	Net Profit/(Loss) from ordinary activities before tax	16.16	10.87	19.83	27.03	30.90	102.62
3	Net Profit/(Loss) from ordinary activities after tax	12.09	8.00	14.91	20.10	23.19	76.88
4	Total Comprehensive Income for the period [comprising Profit/ (Loss) after tax] and Other Comprehensive Income (after tax)	12.09	8.00	18.07	20.10	25.59	79.28
5	Paid up equity share Capital (Face value Rs 10/-)	997.95	831.63	831.63	831.63	831.63	831.63
6	Earning Per Share (EPS in ₹) (Not annualised) (Basic, Diluted)	0.12	0.08	0.15	0.20	0.24	0.79

**Notes:**

- The above unaudited results were reviewed by the Audit Committee of the Board on 8th November 2023 and approved by the Board of Directors at their meeting held on the same date. The Statutory Auditors of the Company have carried Limited Review of aforesaid results.
- The above is an extract of the details format of Quarter and Half Year Ended Results filed with the stock exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The full format of the Quarter and Half Year ended Financial Results are available on stock exchange website at [www.bseindia.com](http://www.bseindia.com) and also on the company's website i.e. [www.ekolifesciences.com](http://www.ekolifesciences.com)
- The Company issued 55,44,178 equity shares of face value of ₹10/- each ('Rights Equity Shares') to the Eligible Equity Shareholders at an issue price of ₹45 per Rights Equity Share (including premium of ₹35 per Rights Equity Share). The Rights Equity Shares were issued as partly paid-up and an amount of ₹13.50 per Rights Equity Share was payable on application (of which ₹3 towards face value of Rights Equity Share and ₹10.5 towards premium amount of Rights Equity Share). Balance to be payable in one or more call. There is no deviation in use of proceeds from the objects stated in the Offer document for rights issue.

For Eiko Lifesciences Limited  
Sd/-  
**Laxmikant Kabra**  
Chairman & Director  
DIN: 00061346

Date : 08/11/2023  
Place: Thane

**EIKO LIFESCIENCES LIMITED**

FEEL THE CHEMISTRY

[Formerly known as Narendra Investments (Delhi) Ltd.]

(CIN: L65903MH1977PLC258134)

Regd off: 604, Centrum, Opp. TMC Office, Near Satkar Grand Hotel, Wagle Estate, Thane West MH 400604

**EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2023**  
(₹ in Lakhs Except EPS)

Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31-03-2023
		(Unaudited)	(Unaudited)	(Unaudited)	(unaudited)	(unaudited)	(Audited)
1	Total Income from Operations	644.09	653.50	453.62	1,297.59	781.19	1,917.62
2	Net Profit/(Loss) from ordinary activities before tax	16.16	10.87	19.83	27.03	30.90	102.62
3	Net Profit/(Loss) from ordinary activities after tax	12.09	8.00	14.91	20.10	23.19	78.88
4	Total Comprehensive Income for the period (comprising Profit/(Loss) after tax and Other Comprehensive Income (after tax))	12.09	8.00	18.07	20.10	25.59	79.28
5	Paid up equity share Capital (Face value ₹s 10/-)	997.95	831.63	831.63	831.63	831.63	831.63
6	Earning Per Share (EPS in ₹) (Not annualised) (Basic, Diluted)	0.12	0.08	0.15	0.20	0.24	0.79

**Notes:**

- The above unaudited results were reviewed by the Audit Committee of the Board on 8th November 2023 and approved by the Board of Directors at their meeting held on the same date. The Statutory Auditors of the Company have carried Limited Review of aforesaid results.
- The above is an extract of the details format of Quarter and Half Year Ended Results filed with the stock exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The full format of the Quarter and Half Year ended Financial Results are available on stock exchange website at [www.bseindia.com](http://www.bseindia.com) and also on the company's website i.e. [www.eikolifesciences.com](http://www.eikolifesciences.com)
- The Company issued 55,44,178 equity shares of face value of ₹10/- each ('Rights Equity Shares') to the Eligible Equity Shareholders at an issue price of ₹45 per Rights Equity Share (including premium of ₹35 per Rights Equity Share). The Rights Equity Shares were issued as partly paid-up and an amount of ₹13.50 per Rights Equity Share was payable on application (of which ₹3 towards face value of Rights Equity Share and ₹10.5 towards premium amount of Rights Equity Share). Balance to be payable in one or more call. There is no deviation in use of proceeds from the objects stated in the Offer document for rights issue.

For Eiko Lifesciences Limited

Sd/-

Laxmikant Kabra

Chairman & Director

DIN: 00061346

Date : 08/11/2023

Place: Thane